Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cf7f3f36d20185ce15a2d1f04d5fdc1 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
filingDate |
2008-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaaaee5db10fda39668429fcc34e3075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b347e5c8546c90e7e24edbfff163d53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1043003b62cf0cc334acfe8ede1cb066 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e4c0be0a29b9b1a178707d5852a3156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32b1088e138e278eb4d2eb4849f8d658 |
publicationDate |
2010-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2140861-A1 |
titleOfInvention |
Pharmaceutical dosage form comprising polymeric carrier composition |
abstract |
A pharmaceutical dosage form comprises a solid dispersion product of at least one active ingredient dispersed in a polymeric binder composition, the polymeric carrier composition comprising a) a vinylpyrrolidone homopolymer, wherein at least 95 % by weight of the vinylpyrrolidone homopolymer has a molecular weight distribution within the range of from 1000 to 13 000; and b) a vinylpyrrolidone copolymer having a weight-average molecular weight of from 5000 to 1 500 000. The dosage form is preferably prepared by a melt extrusion process. The polymeric carrier composition exhibits a high drug dissolution power and allows a reduction of the viscosity of the melt without deteriorating the mechanical properties and storage stability of the dosage form. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017032650-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017009865-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020064188-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3628310-A1 |
priorityDate |
2008-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |